Biotech
News Category
VERAXA Biotech Shareholders Overwhelmingly Approve Governance and Financing Measures
Shareholders approved proposals to enhance corporate flexibility, supporting VERAXA's long-term growth strategy and development of its BiTAC technolog...
VERAXA Biotech Advances Bispecific ADC Program VXA-222 Under OmniAb Collaboration
VERAXA Biotech announced the advancement of its bispecific antibody-drug conjugate program VXA-222 after OmniAb completed discovery work, moving the p...
Gerresheimer Opens New Plant in Zhenjiang Dagang, Doubling Production Capacity for Injectable Pharma Packaging in China
Gerresheimer has started operations at a new plant in Zhenjiang Dagang, China, doubling its production capacity for glass primary packaging for inject...
Darwin AG Renamed to Novogenia AG to Unify Corporate and Brand Identities
Darwin AG has officially changed its name to Novogenia AG, aligning its corporate identity with its core operating brand to strengthen its internation...
NanoViricides Advances NV-387 Toward Phase II Trial for Bundibugyo Ebola in DRC
NanoViricides reports progress on its oral gummies formulation of NV-387 for the Bundibugyo ebolavirus outbreak in the DRC, with no approved treatment...
Redwood AI Corp. Added to CSE25 Index, Boosting Visibility Among Investors
Redwood AI Corp.'s inclusion in the CSE25 Index highlights its growth and may attract more institutional and retail investors focused on AI-driven che...
Helus Pharma Reports Fiscal 2026 Results, Phase 3 Trial for Depression Drug on Track
Helus Pharma announced fiscal 2026 financials and progress in its Phase 3 trials for HLP003 in major depressive disorder, with topline data expected i...
Quantum BioPharma's Lucid-MS Offers Novel Approach to Treating Multiple Sclerosis
Quantum BioPharma's first-in-class drug candidate Lucid-MS, which aims to repair myelin damage in multiple sclerosis, is preparing for Phase 2 trials,...
Why Drug Delivery May Be the Next Major Frontier in Oncology Innovation
The $410 billion nanomedicine and advanced drug-delivery market is gaining attention as companies like Oncotelic Therapeutics use platforms such as De...
Quantum BioPharma’s Lucid-MS Targets Myelin Repair in Multiple Sclerosis, Poised for Phase 2 Trials
Quantum BioPharma is advancing Lucid-MS, a first-in-class neuroprotective therapy for multiple sclerosis that directly targets myelin repair, toward P...
VERAXA Biotech Reports Proof-of-Concept Data for BiTAC-ADC Platform, Enhancing Precision in Cancer Therapy
VERAXA Biotech announced new in vitro data showing its BiTAC-ADC platform distinguishes cancer from healthy cells, minimizing toxicity and supporting ...
Redwood AI Corp. Leverages AI to Transform Chemistry R&D
Redwood AI Corp. is highlighted as a company to watch for its AI-powered platforms that accelerate chemistry research and development across pharmaceu...
NanoVirides Receives DRC Approval for Phase II Ebola Trial of NV-387 Oral Gummies
NanoVirides has obtained approval from the Democratic Republic of Congo's Pillar Committee to advance its Phase II clinical trial of NV-387 Oral Gummi...
Helus Pharma Chief Medical Officer to Speak at H.C. Wainwright Neuro Perspectives Conference
Helus Pharma announces its Chief Medical Officer will participate in a fireside chat at a key industry conference, highlighting the company's progress...
Onco-Innovations Advances ONC010 Manufacturing Process Development
Onco-Innovations Limited has initiated process development and scale-up activities for its drug candidate ONC010, a key step toward IND-enabling studi...
Quantum BioPharma Advances LUCID-MS Therapy for Multiple Sclerosis After Positive Phase 1 Results
Quantum BioPharma's LUCID-MS program shows promise in phase 1 trials for addressing myelin damage in multiple sclerosis, a disease affecting millions ...
NeuroOne to Present at Planet MicroCap Las Vegas 2026 Conference
NeuroOne Medical Technologies will present at the Planet MicroCap Las Vegas 2026 Conference on June 17, 2026, providing updates on its OneRF platform ...
GeoVax CEO Highlights Renewed Strategic Interest in Vaccine Platforms and Infectious Disease Innovation
GeoVax Labs comments on recent pharmaceutical acquisitions signaling a strategic shift toward vaccine innovation and health security as long-term prio...
Quantum BioPharma Highlights Lucid-MS and unbuzzd Growth Opportunities on BioMedWire Podcast
Quantum BioPharma discussed its lead drug candidate Lucid-MS for multiple sclerosis and its commercial product unbuzzd on the BioMedWire Podcast, high...
Helus Pharma to Present at Jefferies Global Healthcare Conference
Helus Pharma, a clinical-stage company developing novel serotonergic agonists, announced its participation in the Jefferies Global Healthcare Conferen...
TransCode Therapeutics Initiates Phase 2a Trial of TTX-MC138 in Colorectal Cancer Patients with Minimal Residual Disease
TransCode Therapeutics has started a Phase 2a trial of TTX-MC138 in colorectal cancer patients with minimal residual disease, aiming to reduce recurre...
NanoViricides Highlights NV-387 as Potential Candidate for Bundibugyo Ebola Outbreak
NanoViricides announces that its broad-spectrum antiviral candidate NV-387 warrants evaluation for the Bundibugyo Ebola outbreak, given its host-targe...
SureNano Science Aims to Compete in GLP-1 Obesity Drug Market with Novel Peptide GEP-44
SureNano Science Ltd. is advancing its GLP-1-based therapeutic GEP-44 through FDA development, targeting the booming obesity and metabolic disease mar...
Oncotelic Therapeutics Integrates 28 Million Scientific Abstracts into AI Drug Discovery Platform
Oncotelic Therapeutics has integrated 28 million scientific abstracts into its PDAOAI platform, positioning itself to compete with big pharma in the $...
Telomir Pharmaceuticals Reports Preclinical Data Supporting Telomir-Zn in Wilson’s Disease
Telomir Pharmaceuticals announced peer-reviewed preclinical data showing Telomir-Zn improves survival and reduces oxidative stress and copper burden i...
Lantern Pharma Receives FDA Support for HARMONIC Trial Amendments in Never-Smoker NSCLC
Lantern Pharma announced FDA approval for protocol amendments to its Phase 2 HARMONIC trial, clearing a path for LP-300 in never-smokers with EGFR-mut...
NanoViricides Highlights Broad-Spectrum Antiviral Candidate NV-387 Amid Ebola Outbreak
NanoViricides emphasizes the potential of its oral drug candidate NV-387 as a pandemic preparedness tool against the ongoing Bundibugyo Ebola outbreak...
Quantum BioPharma Reaches Midpoint Enrollment in MS Imaging Study, Promising Preliminary Data
Quantum BioPharma announced that its collaborative multiple sclerosis imaging study with Massachusetts General Hospital has reached midpoint enrollmen...
LIXTE Biotechnology Reports First-Quarter Progress on Oncology Pipeline and Strategic Expansion
LIXTE Biotechnology announced continued advancement of its lead oncology candidate LB-100 and growth at its Liora Technologies subsidiary, underscorin...
Dogwood Therapeutics Reports First Quarter 2026 Financial Results and Pipeline Progress
Dogwood Therapeutics announced financial results for Q1 2026, highlighting progress in its Phase 2b CINP study for Halneuron® and FDA clearance for SP...
CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities
Innovations in central nervous system drug delivery, particularly nose-to-brain platforms, are addressing the blood-brain barrier bottleneck and openi...
Silo Pharma Launches Ibogaine-Based TBI Therapeutics Initiative
Silo Pharma has announced a strategic initiative to develop ibogaine-based therapeutics for traumatic brain injury and related conditions, filing a pr...
Hantavirus Outbreak on Cruise Ship Highlights Risks of Little-Known Infection
Three fatalities on the MV Hondius cruise ship from hantavirus underscore the need for awareness and diagnostic capabilities, benefiting companies lik...
NanoViricides Receives Orphan Drug Designation for NV-387 to Treat Measles Amid Global Outbreaks
NanoViricides' NV-387 obtains FDA Orphan Drug Designation for measles, offering incentives and supporting development against rising global outbreaks.
VolitionRx Achieves Finger-Prick Breakthrough for Nucleosome Detection in Sepsis, Expanding Point-of-Care Potential
VolitionRx announced a technical milestone in detecting nucleosomes in capillary blood from sepsis patients using a finger-prick prototype, which coul...
Helus Pharma Partners With TARA Mind to Support Phase 3 Trial Recruitment in Veterans
Helus Pharma has partnered with TARA Mind to enhance recruitment for its Phase 3 depression trial in veterans, aligning with a recent Executive Order ...
Ventripoint's VMS+ 4.0 Submitted for Regulatory Approval in China via Green Channel Pathway
Ventripoint Diagnostics announced that its AI-powered cardiac imaging system, VMS+ 4.0, has been submitted for NMPA approval in China through an exped...
Formycon AG to Discuss 2025 Financial Results and Outline 2026 Outlook in April 22 Conference Call
Formycon AG will publish its 2025 annual results on April 22, 2026, host a conference call, and participate in multiple international investor confere...
Helus Pharma Appoints Dr. Ken Kramer as SVP of Medical Affairs to Strengthen Neuroscience Pipeline
Helus Pharma announced the appointment of Dr. Ken Kramer as senior vice president of medical affairs, leveraging his 20+ years of neuroscience leaders...
GeoVax Reports 2025 Year-End Financial Results and Provides Business Update
GeoVax plans to initiate a pivotal Phase 3 trial for its GEO-MVA mpox/smallpox vaccine in the second half of 2026, aiming to address global supply con...
Kairos Pharma Honored with 2026 Pinnacle Award for Biotech Innovation in Cancer Drug Resistance
Kairos Pharma's recognition at the 2026 Pinnacle Awards highlights its pioneering work in developing resistance-modulating therapies aimed at overcomi...
HeartBeam Launches Public Offering to Fund Commercialization and AI Growth
HeartBeam Inc. has announced an underwritten public offering to raise capital for the commercialization of its FDA-cleared 12-lead synthesized ECG sys...
Lixte Biotech Advances Precision Oncology With LB-100, Expands Clinical Trials and Partnerships
Lixte Biotech is advancing its lead candidate LB-100, a first-in-class therapy enhancing existing cancer treatments, through strategic partnerships an...
Lixte Biotech Advances Precision Oncology Strategy with LB-100, Expands Clinical and Strategic Partnerships
Lixte Biotechnology is advancing its lead candidate LB-100, a first-in-class therapy that enhances existing cancer treatments, through expanded clinic...
NanoViricides to Initiate Phase II MPox Trial in DRC, Advancing NV-387 Against Clade I Virus
NanoViricides announced plans to start a Phase II clinical trial of its antiviral NV-387 for MPox in the Democratic Republic of Congo, aiming to addre...
BioStem Technologies to Present at the 25th Annual Needham Virtual Healthcare Conference
BioStem Technologies will present at the Needham Virtual Healthcare Conference, highlighting its regenerative medicine products and technologies to in...
Telomir Pharmaceuticals Submits IND for Telomir-1 Targeting Triple-Negative Breast Cancer
Telomir Pharmaceuticals has submitted an Investigational New Drug application to the FDA for Telomir-1, a novel oral therapy for advanced triple-negat...
Ketryx Launches First-of-Its-Kind Validated AI Conference for Regulated Industries
Ketryx announces its inaugural Validated AI Conference, a first-of-its-kind event uniting professionals building AI in regulated environments to share...